China Health Group Inc.

China Health Group Inc.

HHKEX:8225
0.07
HKD
+0.00
(-1.43%)
99.54MMarket Cap
China Health Group Inc.
HKEX:8225
(Hong Kong Exchange)

Recent

price

0.07

P/E

ratio

- -

div

yld

- -

ROIC.AI

2008
2009
2010
2011
2012
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
0.06
0.09
0.07
0.03
0.05
0.02
0.02
0.06
0.06
0.06
0.08
0.08
0.01
0.02
0.03
0.03
- -
Revenue per Share
-0.02
0.01
-0.1
-0.28
0.01
- -
- -
0.03
0.02
0.03
0.06
0.04
-0.02
-0.06
-0.01
-0.02
- -
Basic EPS, GAAP
-0.05
0.01
-0.02
0.01
-0.01
- -
-0.01
0.01
- -
- -
0.02
-0.01
-0.01
- -
0.01
0.01
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.19
0.21
0.1
-0.18
-0.17
-0.04
-0.03
0.01
0.03
0.06
0.12
0.16
0.14
0.09
0.07
0.06
0.09
Book Value per Share
0.17
0.19
0.1
-0.18
-0.17
-0.04
-0.03
0.01
0.03
0.06
0.12
0.16
0.14
0.09
0.07
0.06
0.09
Tangible Book Value per Share
660
542
543
544
545
915
915
993
993
993
994
995
995
995
995
995
995
Basic Weighted Avg Shares
39
47
38
18
29
20
20
58
60
63
83
84
13
21
26
29
- -
Sales/Revenue/Turnover
-51.19
45.21
-50.41
-237.24
-4.63
16.25
14.21
58.07
46.45
51.56
66.3
50.34
-122.67
-272.26
-56.12
-53.04
- -
Operating Margin (%)
4
3
6
3
3
1
1
1
1
1
- -
- -
- -
- -
1
1
- -
Depreciation Expense
-16
6
-57
-154
3
-3
2
30
23
28
61
36
-16
-58
-15
-15
- -
Net Income, GAAP
- -
4.39
- -
- -
3.5
- -
- -
10.16
16.28
14.36
14.33
14.57
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-41.73
13.27
-151.05
-849.75
10.87
-16.36
10.51
52.07
38.86
43.96
73.02
43.45
-120.9
-270.78
-54.88
-52.38
- -
Profit Margin (%)
143
164
142
-108
-12
-44
-29
3
26
55
117
154
140
77
61
47
83
Working Capital
66
78
108
- -
92
- -
- -
- -
- -
3
- -
- -
- -
- -
- -
- -
- -
LT Debt
106
113
56
-97
-94
-40
-25
6
29
57
119
156
142
84
70
55
92
Total Equity
- -
5.97
- -
- -
- -
- -
- -
-1,511.75
87.77
46.63
42.21
22.14
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
3.84
- -
- -
125.99
- -
- -
-639.81
127.24
60.88
67.07
26.36
- -
- -
- -
- -
- -
Return on Capital (%)
-14.51
5.8
-68.26
- -
- -
- -
- -
- -
132.4
64.51
69.06
26.49
-10.63
-51.08
-18.71
-23.8
- -
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Sep'23
Dec'23
Jun'24
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
995
995
995
Market Capitalization
136
125
93

Working Capital

CNY

•

in mil. unless spec.
Sep'23
Dec'23
Jun'24
Total Current Assets
- -
112
120
Cash, Cash Equivalents & STI
- -
7
9
Accounts Receivable, Net
- -
64
75
Inventories
- -
- -
- -
Total Current Liabilities
- -
35
37
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
38.97%
-11.4%
-21.46%
Free Cash Flow
-536.94%
-98.9%
-11.09%
Net Income, GAAP
129.36%
2.19%
3.05%
Sales/Revenue/Turnover
23.85%
2.29%
7.98%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
26
2025
- -
- -
29
2026
- -
- -
- -

Semi-annual Earnings Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
-0.01
2025
- -
- -
-0.02
2026
- -
- -
- -

Semi-annual Dividends Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -
Business
China Health Group Inc. (Ticker: 8225.HK) is a health-focused company primarily engaged in the manufacturing, distribution, and retail of medical and healthcare products and services. The company's core offerings include pharmaceutical manufacturing; provision and sale of healthcare and wellness products; operation of medical and health management services; pharmaceutical retail; and distribution of medical equipment and supplies. Its product portfolio encompasses traditional Chinese medicine, Western medicines, nutritional supplements, medical devices, and health-related consumer goods. The company operates predominantly in China, targeting healthcare institutions, pharmacies, and end consumers with an emphasis on integrating traditional and modern medical practices. Founded in 2007 and headquartered in Hong Kong, China Health Group Inc. has recently engaged in strategic initiatives to expand its market presence and service offerings. In the past 1-2 years, the company has pursued strategic partnerships aimed at enhancing its pharmaceutical distribution network and expanding digital health management services. It has also launched new product lines incorporating advanced medical technologies and integrated health solutions to address emerging market demands for personalized healthcare. These initiatives align with its broader strategic shift towards becoming a comprehensive healthcare provider, combining product manufacturing, distribution, retail, and health management services under one umbrella. The company continues to leverage its position in China's growing healthcare sector by strengthening operational capabilities and expanding its footprint across key regional markets. China Health Group operates in the healthcare and pharmaceutical industry segment with a business model that incorporates manufacturing, distribution, retail, and healthcare service delivery. Its target markets include hospitals, clinics, pharmacies, health-conscious consumers, and wellness centers across mainland China and Hong Kong. The company has several subsidiaries focusing on different aspects of healthcare delivery and product development, enabling it to provide a wide range of medical and health-related products and services within the Greater China region. Overall, China Health Group Inc. positions itself as a diversified healthcare conglomerate focused on delivering integrated medical and healthcare solutions through product innovation, strategic partnerships, and comprehensive service offerings in China’s evolving healthcare market.